Yi-844 Combined Anti-Inflammatory and Anti-Atherogenic Activity of Natural Drug Inflaminat — A Perspective for Long-Term Atherosclerosis Prevention and Treatment

Gorchakova, T.V.; Супрун, Є. В.; Sobenin, Igor A.; Orekhov, A.N.

doi:10.1016/s1567-5688(07)71854-8

Cited by 5 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several publications report the efficiency of different natural substances for suppressing the production of IL-1, IL-6 and Tumor necrosis factor alpha (TNFα). The aim of our research was to develop a natural non-pharmaceutical product with anti-inflammatory activity to be used in patients with diagnosed atherosclerosis as a supportive therapy [61].…”

Section: Inflaminat Developmentmentioning

confidence: 99%

“…The resulting commercial natural non-pharmaceutical product was named Inflaminat (INAT-Pharma, Russia). It contained equal concentrations of active compounds in a capsule form [61].…”

Section: Inflaminat Developmentmentioning

confidence: 99%

“…The simultaneous suppressing effect of the combination of these herbs (Inflaminat) on cholesterol accumulation in cells and production of pro-inflammatory cytokines was evaluated in laboratory studies using in vitro and ex vivo models. Next, a clinical trial of the natural non-pharmaceutical drug Inflaminat was performed [61,62].…”

Section: Clinical Trial Of Inflaminatmentioning

confidence: 99%

“…Treatment with Inflaminat also had positive effects on different cardiovascular risk factors and caused the lowering of the prognostic risks of ischemic heart disease and myocardial infarction. Thus, Inflaminat can be recommended as a non-pharmaceutical natural product for the long-term prevention of atherosclerosis [61,62].…”

Section: Safetymentioning

confidence: 99%

See 3 more Smart Citations

Blood Serum Atherogenicity: Cellular Test for the Development of Anti- Atherosclerotic Therapy

Myasoedova

Ivashinnikova²,

Собенин

et al. 2017

CPD

View full text Add to dashboard Cite

Atherosclerosis is one of the main problems in modern medical practice. This multifactorial disease can remain asymptomatic for a long time before manifesting itself in cardiovascular disorders, causing ischemic heart disease, myocardial infarction and even sudden death. Many synthetic drugs have been developed to reduce the symptoms of atherosclerosis, however, their efficacy in terms of reduction of atherosclerotic lesions progression is a matter of debate. Adverse effects of the exiting therapy should also be taken into account. The development of cellular models and improved understanding of the mechanisms of atherogenesis at the vascular wall level helped establishing the "direct anti-atherosclerosis therapy" approach. In this approach, the decrease of intracellular lipid deposition and atherogenicity of human blood serum are considered primary (direct) antiatherosclerotic effects. Screening of synthetic and natural substances for anti-atherosclerotic activity revealed a number of botanicals that could be used for direct anti-atherosclerotic therapy to treat early-stage atherosclerosis. As a result, 3 novel non-pharmaceutical products were developed (Allicor, Inflaminat and Karinat). Studies on in vitro and ex vivo models of atherogenesis confirmed their anti-atherosclerotic and anti-atherogenic activities and safety in patients. Clinical studies of Allicor, Inflminat and Karinat were carried out in subjects with diagnosed early stage atherosclerosis, demonstrating a clinically significant anti-atherosclerotic effect of the drugs. In this overview, we will present the complete process of the development of novel non-pharmaceutical products and report the results obtained in the conducted pre-clinical and clinical studies of these medications.

show abstract

Section: Inflaminat Developmentmentioning

confidence: 99%

“…The resulting commercial natural non-pharmaceutical product was named Inflaminat (INAT-Pharma, Russia). It contained equal concentrations of active compounds in a capsule form [61].…”

Section: Inflaminat Developmentmentioning

confidence: 99%

Section: Clinical Trial Of Inflaminatmentioning

confidence: 99%

Section: Safetymentioning

confidence: 99%

See 2 more Smart Citations

Blood Serum Atherogenicity: Cellular Test for the Development of Anti- Atherosclerotic Therapy

Myasoedova

Ivashinnikova²,

Собенин

et al. 2017

CPD

View full text Add to dashboard Cite

show abstract

“…), were demonstrated to possess not only anti-inflammatory, but also antiatherosclerotic effects [81][82][83]. The combination of these herbs was used for the development of a novel dietary supplement (Inflaminat, INAT-Farma, Russia) [84]. The effect of Inflaminat on cIMT dynamics was evaluated in a pilot placebo-controlled double-blinded study performed on 67 asymptomatic men (ClinicalTrials.gov Identifier, NCT01743404) [39,85].…”

Section: Clinical Studiesmentioning

confidence: 99%

Intracellular Cholesterol Lowering as Novel Target for Anti‐Atherosclerotic Therapy

Orekhov¹,

Ivanova²

2016

Cholesterol Lowering Therapies and Drugs

View full text Add to dashboard Cite

Atherosclerosis and disorders associated with cardiovascular system remain the major problem of modern medicine and the leading cause of mortality in developed countries. According to the current knowledge, atherosclerosis development can begin early in life. Clinically silent early-stage lesions can be detected in a large population of young adults. Despite substantial progress in the recent years, therapy of atherosclerosis mostly remains limited to plasma lipid profile correction. Moreover, no therapy is currently available for the treatment of asymptomatic early stages of the disease. The existing synthetic drugs could not be used for this purpose, because of the unfavourable risk/benefit ratio and high cost of treatment, which has to be long-lasting. In this regard, medications based on natural agents with anti-atherosclerotic activity may offer interesting possibilities. Current research should focus on detection and evaluation of such agents. One of the important tools for anti-atherosclerotic drug evaluation is a cellbased model, which allows measurement of intracellular lipid accumulation. Antiatherosclerotic activity of various substances can therefore be evaluated by the decrease of intracellular lipid storage. In this chapter, we will discuss the development and application of cellular models based on primary culture of human arterial wall cells that are suitable for detection and measurement of anti-atherosclerotic activity of various substances. Using these models, several natural agents have been successfully evaluated, which led to the development of pharmaceutical products with antiatherosclerotic activity based on botanicals.

show abstract

Cellular models of atherosclerosis and their implication for testing natural substances with anti-atherosclerotic potential

Orekhov

Ivanova

2016

Phytomedicine

View full text Add to dashboard Cite

Yi-844 Combined Anti-Inflammatory and Anti-Atherogenic Activity of Natural Drug Inflaminat — A Perspective for Long-Term Atherosclerosis Prevention and Treatment

Cited by 5 publications

References 0 publications

Blood Serum Atherogenicity: Cellular Test for the Development of Anti- Atherosclerotic Therapy

Blood Serum Atherogenicity: Cellular Test for the Development of Anti- Atherosclerotic Therapy

Intracellular Cholesterol Lowering as Novel Target for Anti‐Atherosclerotic Therapy

Cellular models of atherosclerosis and their implication for testing natural substances with anti-atherosclerotic potential

Contact Info

Product

Resources

About